KalVista Posts 154% Expense Jump in Q1

KalVista Pharmaceuticals (NASDAQ:KALV), a biopharmaceutical company developing and commercializing therapies for rare diseases, announced its earnings for the first quarter of fiscal 2026 on Sept. 11, 2025. The major headline was the commercial launch of EKTERLY (sebetralstat), the first and only oral treatment for acute hereditary angioedema (HAE) attacks, which received both U.S. Food and Drug Administration (FDA) and United Kingdom regulatory approval during the quarter.

While early patient uptake exceeded management expectations, this achievement was accompanied by a significant surge in commercialization costs, highlighting both the scale of the market opportunity and the operational and financial challenges ahead. The quarter marked a major transition for the company as it moves from research focus to commercial operations.

Source: KalVista Pharmaceuticals. Note: Fiscal 2026's first quarter ended July 31, 2025. Fiscal 2025's Q1 ended July 31, 2024.

Continue reading

Source Fool.com